CA2255910A1 - Methodes de traitement de l'hypertension - Google Patents

Methodes de traitement de l'hypertension Download PDF

Info

Publication number
CA2255910A1
CA2255910A1 CA002255910A CA2255910A CA2255910A1 CA 2255910 A1 CA2255910 A1 CA 2255910A1 CA 002255910 A CA002255910 A CA 002255910A CA 2255910 A CA2255910 A CA 2255910A CA 2255910 A1 CA2255910 A1 CA 2255910A1
Authority
CA
Canada
Prior art keywords
indol
piperidin
compound
amino
tachykinin receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002255910A
Other languages
English (en)
Inventor
Mitchell Irvin Steinberg
Donald Richard Gehlert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2255910A1 publication Critical patent/CA2255910A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention porte sur des méthodes de traitement de l'hypertension pulmonaire consistant à administrer à un mammifère qui le nécessite un composé présentant une activité d'antagoniste du récepteur de la tachykinine.
CA002255910A 1996-05-24 1997-05-23 Methodes de traitement de l'hypertension Abandoned CA2255910A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1826696P 1996-05-24 1996-05-24
US60/018,266 1996-05-24
PCT/US1997/009225 WO1997044035A1 (fr) 1996-05-24 1997-05-23 Methodes de traitement de l'hypertension

Publications (1)

Publication Number Publication Date
CA2255910A1 true CA2255910A1 (fr) 1997-11-27

Family

ID=21787068

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002255910A Abandoned CA2255910A1 (fr) 1996-05-24 1997-05-23 Methodes de traitement de l'hypertension

Country Status (5)

Country Link
EP (1) EP0912178A4 (fr)
JP (1) JP2000511193A (fr)
AU (1) AU3149297A (fr)
CA (1) CA2255910A1 (fr)
WO (1) WO1997044035A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9927125D0 (en) * 1999-11-16 2000-01-12 Univ Reading The Placental human neurokinin B precursor
WO2008090114A1 (fr) 2007-01-24 2008-07-31 Glaxo Group Limited Compositions pharmaceutiques contenant du 2-méthoxy-5- (5-trifluorométhyl-tétrazol-i-yl-benzyl) - (2s-phényl-pipéridin-3s-yl-)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612336A (en) * 1992-07-13 1997-03-18 Merck, Sharp & Dohme Ltd. Heterocyclic amide derivatives as tachykinin antagonists
GB9220286D0 (en) * 1992-09-25 1992-11-11 Merck Sharp & Dohme Therapeutic agents
FR2696178B1 (fr) * 1992-09-30 1994-12-30 Sanofi Elf Amides basiques quaternaires, procédé pour leur préparation et compositions pharmaceutiques en contenant.
US5344830A (en) * 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
US6175013B1 (en) * 1994-06-10 2001-01-16 Eli Lilly And Company Imidazolinyl tachykinin receptor antagonists
ATE178886T1 (de) * 1995-02-22 1999-04-15 Novartis Erfind Verwalt Gmbh 1-aryl-2-acylamino-ethan-verbindungen und ihre verwendung als neurokinin- insbesondere als neurokinin-1-antagonisten
RU2156250C2 (ru) * 1995-04-24 2000-09-20 Новартис Аг Производные хромона, способ их получения и фармацевтическая композиция

Also Published As

Publication number Publication date
AU3149297A (en) 1997-12-09
EP0912178A4 (fr) 2000-08-16
JP2000511193A (ja) 2000-08-29
EP0912178A1 (fr) 1999-05-06
WO1997044035A1 (fr) 1997-11-27

Similar Documents

Publication Publication Date Title
EP0710479B1 (fr) Utilisation d'un agoniste de la sérotonine en combinaison avec un antagoniste du récepteur de la tachykinine pour la fabrication d'un médicament pour la prévention ou le traitement de la migraine
RU2140921C1 (ru) Непептидные антагонисты рецепторов тахикинина
US5492927A (en) Non-peptide tachykinin receptor antagonists to treat allergy
KR100599134B1 (ko) 양성 전립선 비대증에 대한 ｎｋ-1 수용체 길항물질의 용도
EP0714891A1 (fr) Antagonistes hétérocycliques de récepteurs de la tachykinine
JPH10513463A (ja) うっ血性心不全の治療へのカルバゾール化合物の利用
US5990159A (en) Use of 5HT4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhibitors
RU2193557C2 (ru) Бензоциклогептатиофеновые соединения, способы профилактики или лечения, фармацевтическая композиция
HUT71222A (en) Pharmaceutical compositions for inhibiting pulmonary hypertenzive diseases containing 2-phenyl-3-aroyl-benzotiophene derivatives and process for their preparation
US5663192A (en) Heterocyclic neuropeptide Y receptor antagonists
WO1996041633A1 (fr) Methodes de traitement des rhumes et des rhinites allergiques
PT792642E (pt) Metodo pra o tratamentode disturbios com agonistas de estrogenio
WO1997007117A1 (fr) 2-acylaminopropanamines servant de secretagogues de la somatotrophine
NZ263614A (en) Pharmaceutical use of 5-(methylaminosulphonylmethyl)-3- (n-methylpyrrolidin-2-ylmethyl)-1h-indole and of the corresponding -3-(pyrrolidin-2-ylmethyl)-derivative
WO1996041631A1 (fr) Procedes de traitement du rhume et de la rhinite allergique
US5846973A (en) Methods of treating pulmonary hypertension
US5491140A (en) Naphthyl tachykinin receptor antagonists to treat physiological conditions
MXPA01010904A (es) Utilizacion del saredutant y de sus sales farmaceuticamente aceptables para la preparacion de medicamentos utiles en el tratamiento o la prevencion del conjunto de los trastornos del humor, de los trastornos de adaptacion o de los trastornos mixtos a
EP0699665B1 (fr) Dérivés d'imidazoline, leur préparation et leur utilisation comme antagonistes de tachykinin récepteur
CA2255910A1 (fr) Methodes de traitement de l'hypertension
CA2357925A1 (fr) Utilisation prophylactique d'antagonistes du n-methyl-d-aspartate
US6001837A (en) Methods of treating or preventing sleep apnea
WO1997025988A1 (fr) Procedes de traitement ou de prevention de la douleur ou nociception
JP2002527381A (ja) アレルギー性疾患を処置するための組成物および方法
US6017930A (en) Methods of treating or preventing interstitial cystitis

Legal Events

Date Code Title Description
FZDE Dead